Codi QR

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the developmen...

Descripció completa

Guardat en:
Autors principals: Ozhan Ocal, Victor Pashkov, Rahul K. Kollipara, Yalda Zolghadri, Victoria H. Cruz, Michael A. Hale, Blake R. Heath, Alex B. Artyukhin, Alana L. Christie, Pantelis Tsoulfas, James B. Lorens, Galvin H. Swift, Rolf A. Brekken, Thomas M. Wilkie
Format: Artigo
Idioma:Inglês
Publicat: The Company of Biologists 2015-10-01
Col·lecció:Disease Models & Mechanisms
Matèries:
Rgs16::GFP reporter
Kras
Rapid in vivo screen
Pancreatic cancer combination therapy
Gas6
Axl
Warfarin
Gemcitabine
Abraxane
Accés en línia:http://dmm.biologists.org/content/8/10/1201
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars